uniQure raises $242.7 million in follow-on public offering; cash reserves reach $811.9 million

uniQure

uniQure announced a follow-on public offering in June 2026, raising approximately $242.7 million in gross proceeds. Combined with existing cash, the company's total cash, cash equivalents and investments reached $811.9 million as of June 30, 2026, providing strong funding for AMT-130 regulatory submissions and commercialization preparation.

• Follow-on offering raised $242.7 million.
• Q2 2026 cash position: $811.9 million.
• Q2 2026 revenue: $5.8 million, primarily from HEMGENIX royalties.
• R&D expenses: $34.0 million in Q2 2026.
• Capital positioned for AMT-130 regulatory submissions and launch preparation.